NO20082595L - Metastinderivater og deres anvendelse derav - Google Patents
Metastinderivater og deres anvendelse deravInfo
- Publication number
- NO20082595L NO20082595L NO20082595A NO20082595A NO20082595L NO 20082595 L NO20082595 L NO 20082595L NO 20082595 A NO20082595 A NO 20082595A NO 20082595 A NO20082595 A NO 20082595A NO 20082595 L NO20082595 L NO 20082595L
- Authority
- NO
- Norway
- Prior art keywords
- metastine
- hormone secretion
- activity
- suppressive activity
- present
- Prior art date
Links
- 230000001394 metastastic effect Effects 0.000 title 1
- 206010061289 metastatic neoplasm Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 5
- 230000028327 secretion Effects 0.000 abstract 4
- 206010027476 Metastases Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000005907 cancer growth Effects 0.000 abstract 2
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 2
- 230000001456 gonadotroph Effects 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003797 essential amino acid Substances 0.000 abstract 1
- 235000020776 essential amino acid Nutrition 0.000 abstract 1
- 238000001879 gelation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Den foreliggende oppfinnelsen tilveiebringer stabile metastinderivater som har utmerkede biologiske aktiviteter (en cancer metastase undertrykkende aktivitet, en cancer vekst undertrykkende aktivitet, en gonadotropisk hormon sekresjon stimulerende aktivitet, kjønnshormon sekresjon stimulerende aktivitet, og så videre). Ved å substituere de utgjørende aminosyrene av metastin med spesifikke aminosyrer i metastin derivatet av den foreliggende oppfinnelsen, er blod stabilitet, løselighet og så videre mer forbedret, gelateringstendens er redusert, farmakokinetikk er også forbedret, og en utmerket cancer metastase undertrykkende aktivitet eller en cancer vekst undertrykkende aktivitet er vist. Videre har metastin derivatet av den foreliggende oppfinnelsen effektene av å undertrykke gonadotropisk hormon sekresjon, undertrykke kjønnshormon sekresjon, og så videre.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005370388 | 2005-12-22 | ||
JP2006275843 | 2006-10-06 | ||
PCT/JP2006/326176 WO2007072997A1 (en) | 2005-12-22 | 2006-12-21 | Metastin derivatives and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20082595L true NO20082595L (no) | 2008-09-22 |
NO341879B1 NO341879B1 (no) | 2018-02-12 |
Family
ID=37846230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082595A NO341879B1 (no) | 2005-12-22 | 2008-06-10 | Metastinderivater og anvendelse derav. |
Country Status (30)
Country | Link |
---|---|
US (1) | US7960348B2 (no) |
EP (1) | EP1963362B1 (no) |
JP (2) | JP4653840B2 (no) |
KR (1) | KR101368607B1 (no) |
AR (1) | AR058584A1 (no) |
AU (1) | AU2006328333B2 (no) |
BR (1) | BRPI0619399B8 (no) |
CA (1) | CA2634647C (no) |
CR (1) | CR10019A (no) |
CY (1) | CY1112353T1 (no) |
DK (1) | DK1963362T3 (no) |
ES (1) | ES2375038T3 (no) |
GE (1) | GEP20115356B (no) |
HK (1) | HK1120809A1 (no) |
HR (1) | HRP20110851T1 (no) |
IL (1) | IL190888A (no) |
JO (1) | JO2799B1 (no) |
MA (1) | MA30060B1 (no) |
ME (1) | ME01015B (no) |
MY (1) | MY151967A (no) |
NO (1) | NO341879B1 (no) |
NZ (1) | NZ568322A (no) |
PE (1) | PE20071141A1 (no) |
PL (1) | PL1963362T3 (no) |
PT (1) | PT1963362E (no) |
RS (1) | RS52007B (no) |
RU (1) | RU2430107C2 (no) |
SI (1) | SI1963362T1 (no) |
TW (1) | TWI386417B (no) |
WO (1) | WO2007072997A1 (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063221A1 (ja) | 2002-12-26 | 2004-07-29 | Takeda Pharmaceutical Company Limited | メタスチン誘導体およびその用途 |
WO2004080479A1 (ja) | 2003-03-12 | 2004-09-23 | Takeda Pharmaceutical Company Limited | 性腺機能改善剤 |
NZ552029A (en) | 2004-06-25 | 2009-01-31 | Takeda Pharmaceutical | Metastin derivatives and use thereof |
US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
WO2009131191A1 (ja) | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
SI2314609T1 (sl) | 2008-07-30 | 2017-05-31 | Takeda Pharmaceutical Company Limited | Derivat metastina in njegova uporaba |
TW201029660A (en) * | 2008-12-29 | 2010-08-16 | Takeda Pharmaceutical | Prophylactic/therapeutic agent for cancer |
AR079657A1 (es) * | 2009-12-22 | 2012-02-08 | Takeda Pharmaceutical | Formulacion de liberacion sostenida |
JP5838173B2 (ja) * | 2010-06-25 | 2016-01-06 | 武田薬品工業株式会社 | 徐放性製剤 |
EP2755690B1 (en) | 2011-08-04 | 2020-04-01 | Merck Sharp & Dohme B.V. | Kisspeptide-pentasaccharide conjugates |
US9517210B2 (en) | 2012-07-12 | 2016-12-13 | Takeda Pharmaceutical Company Limited | Method for producing microcapsule powder |
WO2015112703A1 (en) * | 2014-01-22 | 2015-07-30 | The Johns Hopkins University | Compositions and methods for treating diabetes |
JP6253146B2 (ja) * | 2014-02-04 | 2017-12-27 | 国立大学法人山口大学 | 新規なペプチド誘導体及びこれを含有する医薬 |
IL265696B1 (en) | 2016-09-30 | 2024-04-01 | Sumitomo Pharma Switzerland Gmbh | -(n-acetyl-d-tyrosyl-trans-4-hydroxy-l-propyl-l-asparaginyl-l-threonyl-l-phenylalenyl) hydrazinocarbonyl-l-leucyl-nω-methyl-l-arginyl-l-tryptophanamide for use in assisted reproductive technology. |
ES2912929T3 (es) | 2016-09-30 | 2022-05-30 | Myovant Sciences Gmbh | Métodos de tratamiento de fibromas uterinos y endometriosis |
CN109206481B (zh) * | 2017-07-05 | 2023-08-18 | 尚华医药科技(江西)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL74827A (en) | 1984-05-21 | 1989-06-30 | Salk Inst For Biological Studi | Peptides active as gnrh antagonists and pharmaceutical compositions containing them |
MX9100717A (es) | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
DE69623655T2 (de) | 1995-10-19 | 2003-04-24 | Takeda Chemical Industries Ltd | Chinolinderivate als gnrh antagonisten |
JPH09169735A (ja) | 1995-10-19 | 1997-06-30 | Takeda Chem Ind Ltd | キノリン誘導体、その製造法および用途 |
AU2382097A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
WO1998039448A2 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
JP4486187B2 (ja) | 1998-10-27 | 2010-06-23 | 武田薬品工業株式会社 | 新規g蛋白質共役型レセプター蛋白質、そのdnaおよびそのリガンド |
US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
IL147180A0 (en) | 1999-06-28 | 2002-08-14 | Basf Ag | Method for preventing tumoral growth |
MXPA02001174A (es) | 1999-08-02 | 2002-07-30 | Archer Daniels Midland Co | Ingenieria metabolica de la produccion de aminoacidos. |
WO2001044469A1 (fr) | 1999-12-17 | 2001-06-21 | Takeda Chemical Industries, Ltd. | PROCEDE DE PRODUCTION DE PEPTIDE KiSS-1 |
JP2004526401A (ja) | 2000-03-29 | 2004-09-02 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
EP1273658A4 (en) | 2000-03-30 | 2004-08-11 | Takeda Chemical Industries Ltd | NEW PROTEIN, THEIR DNA AND METHOD FOR THE PRODUCTION THEREOF |
US7834141B1 (en) | 2000-03-31 | 2010-11-16 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy |
RU2311920C2 (ru) | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
JP2003026601A (ja) | 2000-11-29 | 2003-01-29 | Takeda Chem Ind Ltd | 医薬組成物およびその製造法 |
JP2002320496A (ja) | 2001-02-26 | 2002-11-05 | Takeda Chem Ind Ltd | 新規マウス型KiSS−1レセプタータンパク質およびそのDNA |
WO2002085399A1 (en) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Peptide-containing preparations |
WO2002092829A1 (fr) | 2001-05-17 | 2002-11-21 | Takeda Chemical Industries, Ltd. | Procede de production d'un peptide |
EP1428835B1 (en) * | 2001-09-19 | 2007-04-18 | Takeda Pharmaceutical Company Limited | Antibody against metastin and use of the same in the diagnosis of pregnancy |
EP1466976A4 (en) | 2002-01-11 | 2005-11-09 | Takeda Pharmaceutical | PROCESS FOR PREPARING KISS-1 PEPTIDES |
JP2003300906A (ja) | 2002-04-12 | 2003-10-21 | Daiichi Fine Chemical Co Ltd | がん転移抑制因子の安定化 |
CA2503164A1 (en) | 2002-10-25 | 2004-05-06 | Paradigm Therapeutics Limited | Gpr54 knock-out mammals and screening methods using them |
WO2004063221A1 (ja) | 2002-12-26 | 2004-07-29 | Takeda Pharmaceutical Company Limited | メタスチン誘導体およびその用途 |
JP4804714B2 (ja) * | 2002-12-26 | 2011-11-02 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
US6800611B2 (en) * | 2003-01-06 | 2004-10-05 | Takeda Chemical Industries, Ltd. | Metastin derivatives and their use |
KR100595364B1 (ko) | 2003-02-20 | 2006-07-03 | 재단법인 목암생명공학연구소 | Lk8 단백질을 유효성분으로 포함하는 항암제 |
WO2004080479A1 (ja) | 2003-03-12 | 2004-09-23 | Takeda Pharmaceutical Company Limited | 性腺機能改善剤 |
EP1464652A1 (en) | 2003-04-02 | 2004-10-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases |
US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
US20050026224A1 (en) | 2003-04-28 | 2005-02-03 | Follettie Maximillian T. | Methods and compositions for modulating G-protein coupled receptor 54 |
WO2004101747A2 (en) | 2003-05-07 | 2004-11-25 | The General Hospital Corporation | Identification and use of gpr54 and its ligands for reproductive disorders and contraception |
ATE399763T1 (de) * | 2003-05-30 | 2008-07-15 | Prozymex As | Proteasehemmer |
CA2544473C (en) | 2003-11-03 | 2013-08-13 | Beijing Sunbio Biotech Co., Ltd. | A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof |
RU2333221C2 (ru) | 2003-11-03 | 2008-09-10 | Бейцзин Санбио Байотек Ко., Лтд. | Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение |
WO2005095973A2 (en) | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) |
NZ552029A (en) * | 2004-06-25 | 2009-01-31 | Takeda Pharmaceutical | Metastin derivatives and use thereof |
US7725869B1 (en) * | 2005-04-07 | 2010-05-25 | Xilinx, Inc. | Method and apparatus for modeling multiple instances of an electronic circuit using an imperative programming language description |
WO2007084211A2 (en) | 2005-11-11 | 2007-07-26 | The General Hospital Corporation | Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception |
US20090099334A1 (en) * | 2005-12-22 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
US8404643B2 (en) * | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
-
2006
- 2006-12-20 TW TW095147852A patent/TWI386417B/zh active
- 2006-12-20 AR ARP060105651A patent/AR058584A1/es active IP Right Grant
- 2006-12-21 JP JP2008529406A patent/JP4653840B2/ja active Active
- 2006-12-21 US US12/158,251 patent/US7960348B2/en active Active
- 2006-12-21 BR BRPI0619399A patent/BRPI0619399B8/pt active IP Right Grant
- 2006-12-21 ES ES06843555T patent/ES2375038T3/es active Active
- 2006-12-21 NZ NZ568322A patent/NZ568322A/en unknown
- 2006-12-21 RS RS20110437A patent/RS52007B/en unknown
- 2006-12-21 KR KR1020087012506A patent/KR101368607B1/ko active IP Right Grant
- 2006-12-21 PT PT06843555T patent/PT1963362E/pt unknown
- 2006-12-21 AU AU2006328333A patent/AU2006328333B2/en active Active
- 2006-12-21 JO JO2006486A patent/JO2799B1/en active
- 2006-12-21 PE PE2006001686A patent/PE20071141A1/es active IP Right Grant
- 2006-12-21 GE GEAP200610770A patent/GEP20115356B/en unknown
- 2006-12-21 EP EP06843555A patent/EP1963362B1/en active Active
- 2006-12-21 ME MEP-2009-175A patent/ME01015B/me unknown
- 2006-12-21 PL PL06843555T patent/PL1963362T3/pl unknown
- 2006-12-21 RU RU2008125063/04A patent/RU2430107C2/ru active
- 2006-12-21 CA CA2634647A patent/CA2634647C/en active Active
- 2006-12-21 MY MYPI20082169 patent/MY151967A/en unknown
- 2006-12-21 SI SI200631152T patent/SI1963362T1/sl unknown
- 2006-12-21 WO PCT/JP2006/326176 patent/WO2007072997A1/en active Application Filing
- 2006-12-21 DK DK06843555.1T patent/DK1963362T3/da active
-
2008
- 2008-04-15 IL IL190888A patent/IL190888A/en active IP Right Grant
- 2008-05-26 CR CR10019A patent/CR10019A/es unknown
- 2008-06-10 NO NO20082595A patent/NO341879B1/no unknown
- 2008-06-18 MA MA31044A patent/MA30060B1/fr unknown
- 2008-11-12 HK HK08112400.1A patent/HK1120809A1/xx unknown
-
2010
- 2010-08-17 JP JP2010182482A patent/JP5298087B2/ja active Active
-
2011
- 2011-11-15 HR HR20110851T patent/HRP20110851T1/hr unknown
- 2011-11-18 CY CY20111101116T patent/CY1112353T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082595L (no) | Metastinderivater og deres anvendelse derav | |
NO341584B1 (no) | Metastin derivater og anvendelse derav | |
SG153865A1 (en) | Metastin derivatives and use thereof | |
EA200800555A1 (ru) | Производные ксантина в качестве селективных агонистов hm74a | |
DK1768490T3 (da) | Systemer og fremgangsmåder til ex-vivo-organpleje | |
EA200801372A1 (ru) | Способы получения замещенных пиримидинов | |
ATE496060T1 (de) | Proteinartige verbindungen und anwendungen davon | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
EP1878725A3 (en) | Pyrimidine derivatives and their use as CB2 modulators | |
TW200631592A (en) | Soluble, stable insulin-containing formulations | |
UY29859A1 (es) | Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica | |
CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
EA200802307A1 (ru) | Бинарные смеси гиалуроновой кислоты и их терапевтическое применение | |
UY29857A1 (es) | Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica. | |
CY1115961T1 (el) | Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate) | |
ATE527377T1 (de) | Erstellung von genexpressionprofilen aus ffpe- proben | |
MX2008011473A (es) | El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. | |
ATE506961T1 (de) | Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen | |
ATE472316T1 (de) | Haarbehandlungszusammensetzungen | |
AR108283A2 (es) | Derivados de metastina | |
UA97236C2 (en) | Metastin derivatives and use thereof | |
CY1106950T1 (el) | Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων | |
ATE458482T1 (de) | Verwendung von amino substituierten benzimidazolen | |
MX2009005550A (es) | Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica. | |
DE602004009166D1 (de) | Neue Analoga von Nitrobenzylthioinosin |